clarithromycin has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beltrami, G; Carella, A; Carella, AM; Catania, G; Pica, G | 1 |
| Hughes, TP; Leclercq, TM; Schafranek, L; White, DL | 1 |
2 other study(ies) available for clarithromycin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome | 2012 |
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy.
Topics: Autophagy; Cell Death; Cell Line, Tumor; Clarithromycin; Dasatinib; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2013 |